A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BIIB037 in Japanese Subjects With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Aducanumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Biogen
- 12 Jan 2017 Status changed from active, no longer recruiting to completed.
- 01 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 01 Aug 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.